The team found that some pancreatic cancer cells gain a major survival edge by carrying copies of critical cancer genes—such as MYC—on circular pieces of DNA that exist outside chromosomes, the ...

With the realization that the gross genetic abnormalities that activated MYC in cancer universally led to deregulated expression of the intact coding region, a series of new questions arose.

Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. | Monte Rosa ...

Neuroblastomas are the most common cancer in infants, with about 700–800 diagnoses per year in the US, according to the American Cancer Society. Some of the most high-risk cases are driven by elevated ...

Importantly, we also discovered that certain mutations, like MYC, appear early in prostate cancer development and are linked to more aggressive forms of the disease. If these mutations occur in ...

Monte Rosa announced clinical results from its MRT-6160 Phase 1, single ascending dose / multiple ascending dose study. Details about the ...

Dewpoint will present two posters at AACRCondensate modulators (c-mods) demonstrate robust anti-tumor effects across multiple types of ...

which cause therapeutic vulnerabilities in breast cancer. Our current research specifically focuses on therapeutic strategies aiming to exploit MYC oncogene-induced vulnerabilities and therapeutically ...

The results demonstrated that PRMT5 inhibition significantly suppressed tumor growth across multiple preclinical models, downregulating key ACC-associated genes such as MYB and MYC. The treatment ...